JP2022513959A5 - - Google Patents
Info
- Publication number
- JP2022513959A5 JP2022513959A5 JP2021534681A JP2021534681A JP2022513959A5 JP 2022513959 A5 JP2022513959 A5 JP 2022513959A5 JP 2021534681 A JP2021534681 A JP 2021534681A JP 2021534681 A JP2021534681 A JP 2021534681A JP 2022513959 A5 JP2022513959 A5 JP 2022513959A5
- Authority
- JP
- Japan
- Prior art keywords
- thia
- dioxide
- dipyridina
- trifluoromethyl
- diaza
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783270P | 2018-12-21 | 2018-12-21 | |
| US62/783,270 | 2018-12-21 | ||
| PCT/IB2019/061054 WO2020128925A1 (en) | 2018-12-21 | 2019-12-18 | Macrocyclic compounds and their use in the treatment of disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022513959A JP2022513959A (ja) | 2022-02-09 |
| JP2022513959A5 true JP2022513959A5 (https=) | 2022-11-07 |
Family
ID=69165443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021534681A Pending JP2022513959A (ja) | 2018-12-21 | 2019-12-18 | 大環状化合物及び疾患の処置におけるそれらの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220071971A1 (https=) |
| EP (1) | EP3898621A1 (https=) |
| JP (1) | JP2022513959A (https=) |
| KR (1) | KR20210107046A (https=) |
| CN (1) | CN113227087A (https=) |
| AU (1) | AU2019404934B2 (https=) |
| BR (1) | BR112021011643A2 (https=) |
| CA (1) | CA3119656A1 (https=) |
| MX (1) | MX2021007592A (https=) |
| WO (1) | WO2020128925A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019222758B2 (en) | 2018-02-15 | 2022-07-07 | Vertex Pharmaceuticals Incorporated | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cystic fibrosis, and process for making them |
| TWI848092B (zh) | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
| CA3150162A1 (en) | 2019-08-14 | 2021-02-18 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| TWI899097B (zh) | 2019-08-14 | 2025-10-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| WO2022194399A1 (en) | 2020-07-13 | 2022-09-22 | Idorsia Pharmaceuticals Ltd | Macrocycles as cftr modulators |
| CR20230120A (es) * | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| IL300413A (en) | 2020-08-13 | 2023-04-01 | Vertex Pharma | Crystal forms of CFTR modulators |
| EP4225762A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225765A2 (en) * | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225447A1 (en) * | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| MX2023004074A (es) * | 2020-10-07 | 2023-07-05 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica. |
| AU2021397294A1 (en) | 2020-12-10 | 2023-07-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| EP4308575A1 (en) * | 2021-03-16 | 2024-01-24 | Idorsia Pharmaceuticals Ltd | Macrocycles as cftr modulators |
| TWI904194B (zh) * | 2021-07-12 | 2025-11-11 | 瑞士商愛杜西亞製藥有限公司 | 作為cftr調節劑之巨環 |
| IL315715A (en) * | 2022-04-06 | 2024-11-01 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulation |
| TW202421102A (zh) | 2022-09-15 | 2024-06-01 | 瑞士商愛杜西亞製藥有限公司 | 巨環cftr調節劑與cftr校正子及/或cftr增效劑之組合 |
| CA3267791A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | CRYSTALLINE FORM OF (3S,7S,10R,13R)-13-BENZYL-20-FLUORO-7-ISOBUTYL-N-(2-(3-METHOXY-1,2,4-OXADIAZOL-5-YL)ETHYL)-6,9-DIMETHYL-1,5,8,11-TETRAOXO-10-(2,2,2-TRIFLUOROETHYL)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-TETRADECAHYDRO-[1]OXA[4,7,10,14]TETRAAZACYCLOHEPTADECINO [16,17-F]QUINOLINE-3-CARBOXAMIDE |
| KR20250084132A (ko) | 2022-09-15 | 2025-06-10 | 이도르시아 파마슈티컬스 리미티드 | 마크로시클릭 cftr 조절제 |
| CN115498160B (zh) * | 2022-09-29 | 2025-09-30 | 郑州大学 | 一种锂-有机硫电池正极材料及其制备方法和应用 |
| WO2025186214A1 (en) | 2024-03-05 | 2025-09-12 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9617282B2 (en) * | 2013-03-15 | 2017-04-11 | Biogen Ma Inc. | Macrocyclic compounds as IRAK4 inhibitors for the treatment of inflammatory diseases |
| WO2015138934A1 (en) * | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| US9981945B2 (en) * | 2015-10-07 | 2018-05-29 | NuBridge BioSciences | Pyrimidine derivatives as CFTR modulators |
| TW201811766A (zh) * | 2016-08-29 | 2018-04-01 | 瑞士商諾華公司 | N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途 |
| EP3580224B1 (en) * | 2017-02-07 | 2022-07-13 | Biogen MA Inc. | Ask1 inhibiting agents |
| AU2019222758B2 (en) * | 2018-02-15 | 2022-07-07 | Vertex Pharmaceuticals Incorporated | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cystic fibrosis, and process for making them |
-
2019
- 2019-12-18 CA CA3119656A patent/CA3119656A1/en active Pending
- 2019-12-18 EP EP19836572.8A patent/EP3898621A1/en not_active Withdrawn
- 2019-12-18 BR BR112021011643-5A patent/BR112021011643A2/pt not_active IP Right Cessation
- 2019-12-18 JP JP2021534681A patent/JP2022513959A/ja active Pending
- 2019-12-18 CN CN201980083703.6A patent/CN113227087A/zh active Pending
- 2019-12-18 US US17/415,335 patent/US20220071971A1/en not_active Abandoned
- 2019-12-18 AU AU2019404934A patent/AU2019404934B2/en not_active Ceased
- 2019-12-18 MX MX2021007592A patent/MX2021007592A/es unknown
- 2019-12-18 WO PCT/IB2019/061054 patent/WO2020128925A1/en not_active Ceased
- 2019-12-18 KR KR1020217022294A patent/KR20210107046A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022513959A5 (https=) | ||
| JP2022513959A (ja) | 大環状化合物及び疾患の処置におけるそれらの使用 | |
| JP7721517B2 (ja) | Ｃｆｔｒ活性の欠損が介在する状態を治療するための５員ヘテロアリールアミノスルホンアミド | |
| JP7035055B2 (ja) | Ｎ－（ピリジン－２－イル）ピリジン－スルホンアミド誘導体および疾患の処置におけるそれらの使用 | |
| TWI703154B (zh) | 作為鈉通道調節劑之吡啶酮醯胺之前藥 | |
| ES2857687T3 (es) | Piridona amidas como moduladores de los canales de sodio | |
| IL292965A (en) | Heteroarylaminosulfonamides with 6 positions and methods of using them | |
| CA2787248C (en) | Piperazine compound having a pgds inhibitory effect | |
| TW200930703A (en) | Quinolone derivative | |
| JP2022519301A (ja) | Ｎ－（ピリジン－２－イル）ピリジン－スルホンアミド誘導体及び疾患の処置におけるそれらの使用 | |
| CA3111649A1 (en) | Tricyclic compounds acting on crbn proteins | |
| TW201623295A (zh) | 具有ｂａｃｅ１抑制活性之二氫噻及二氫衍生物 | |
| CN105085482B (zh) | 取代的哌嗪化合物及其使用方法和用途 | |
| JP2022514253A (ja) | Ｎ－（ピリジン－２－イルスルホニル）シクロプロパンカルボキサミド誘導体及びｃｆｔｒ媒介疾患の処置におけるその使用 | |
| US20230159439A1 (en) | Arylamides and methods of use thereof | |
| RU2804139C2 (ru) | Макроциклические соединения и их применение в лечении заболевания | |
| WO2025129104A1 (en) | Compounds, compositions, and methods of using thereof | |
| AU2023283549A1 (en) | Compounds, compositions, and methods of using thereof | |
| OA21686A (en) | 5-Membered heteroarylamino-sulfonamides for treating conditions mediated by deficient CFTR activity. |